WHO on the vaccine rush: It's not a race between countries or companies
Officials working on the World Health Organization's Access to COVID-19 Tools (ACT) Accelerator -- a global collaboration to accelerate the development and access to COVID diagnostics and treatments -- said the organization had received $2.7 billion in funding for the venture, which is less than 10% of the overall cost.
The organization also revealed that it experienced some setbacks in the Oxford coronavirus vaccine trial, saying there "was a severe side event and therefore the trial was halted."
"This is normal procedure and good clinical practice because safety is the highest priority in any clinical trial," Dr. Soumya Swaminathan, the organization's chief scientist, said. "This is perhaps a lesson, or a wakeup call, for everyone to recognize the fact that there are ups and downs in research, there are ups and downs in clinical development and we have to be prepared for those. It's not always a fast and a straight road."
She added, "But we don't need to be overly discouraged because these things happen, and we have to wait for the determination."
She said clinical trials typically take at least six months to complete. With some vaccine trails having started as early as June, she said officials could receive interim results by the end of the year or early 2021.
"It's a race against this virus and it's a race to save lives. It's not a race between companies, it's not a race between countries," WHO Emergencies Chief Dr. Mike Ryan said. "It's a race to support public health in the safest most effective way possible. That's the race we're in."